Thrombosis in the critically ill neonate: incidence, diagnosis, and management by Veldman, Alex et al.
© 2008   Veldman et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2008:4(6) 1337–1348 1337
REVIEW
Thrombosis in the critically ill neonate: incidence, 
diagnosis, and management
Alex Veldman1
Marcel F Nold2
Ina Michel-Behnke3
1Monash Newborn and Ritchie 
Centre for Baby Health Research, 
Monash Medical Centre and Monash 
Institute of Medical Research, 
Melbourne, VIC, Australia;  2Dept 
of Medicine, University of Colorado 
Health Sciences Center, Denver, CO, 
USA; 3Dept of Pediatric Cardiology, 
Pediatric University Hospital, Vienna, 
Austria
Correspondence:   Alex Veldman
Monash Newborn, Monash Medical 
Centre, 246 Clayton RD, Clayton 3168, 
Melbourne, VIC, Australia
Tel +61 3 9594 5155
Fax +61 3 9594 6115
Email alex.veldman@med.monash.edu.au
Abstract: Among children, newborn infants are most vulnerable to development of 
thrombosis and serious thromboembolic complications. Amongst newborns, those neonates 
who are critically ill, both term and preterm, are at greatest risk for developing symptomatic 
thromboembolic disease. The most important risk factors are inﬂ  ammation, DIC, impaired 
liver function, ﬂ  uctuations in cardiac output, and congenital heart disease, as well as exogenous 
risk factors such as central venous or arterial catheters. In most clinically symptomatic infants, 
diagnosis is made by ultrasound, venography, or CT or MRI angiograms. However, clinically 
asymptomatic vessel thrombosis is sometimes picked up by screening investigations or during 
routine imaging for other indications. Acute management of thrombosis and thromboembolism 
comprises a variety of approaches, including simple observation, treatment with unfractionated 
or low molecular weight heparin, as well as more aggressive interventions such as thrombolytic 
therapy or catheter-directed revascularization. Long-term follow-up is dependent on the 
underlying diagnosis. In the majority of infants, stabilization of the patients’ general condi-
tion and hemodynamics, which allows removal of indwelling catheters, renders long-term 
anticoagulation superﬂ  uous. Nevertheless, in certain types of congenital heart disease or inher-
ited thrombophilia, long-term prophylaxis may be warranted. This review article focuses on 
pathophysiology, diagnosis, and acute and long-term management of thrombosis in critically 
ill term and preterm neonates.
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Introduction
The group of critically ill newborns presents the largest patient population in childhood 
suffering from thromboembolism. Making decisions regarding therapeutic strategies 
is a challenge for the intensive care physician as the clinical signiﬁ  cance of neonatal 
thrombosis varies from asymptomatic incidents to life-or limb-threatening events; 
moreover, appropriate evidence-based treatment algorithms are lacking.
This review article focuses on the pathophysiology, diagnosis and acute, as well as 
long-term, management of thrombosis in critically ill term and preterm neonates.
Incidence
A commonly cited paper published in 1995 reported that approximately 2.4/1000 
of newborns admitted to neonatal intensive care units experience a symptomatic 
thromboembolic event (TE) (Schmidt and Andrew 1995). Another study from 
Germany reported an incidence of 5.1 per 100.000 live births in the period from 
1992 to 1994 (Nowak-Gottl et al 1997). However, these numbers are expected to 
have been on the rise since that time as a result of ever more invasive therapeutic 
interventions, including an increasing use of central venous catheters (CVC), venous 
and arterial umbilical catheters (UVC and UAC), as well as other arterial catheters. 
For example, today 15% of all babies admitted to neonatal intensive care unit (NICU) Vascular Health and Risk Management 2008:4(6) 1338
Veldman et al
and 50% of all preterm neonates with a birth weight of 
1000 g are instrumented with an umbilical venous catheter 
(Seguin et al 1994). Unfortunately, together with asphyxia, 
sepsis, and prematurity, catheterization is among the most 
important risk factors for thrombosis in the neonatal period 
(Nowak-Gottl et al 1997; Kuhle et al 2004).
It is very difﬁ  cult to estimate the true incidence of 
CVC-associated TE. While clinical studies report inci-
dences from 13% up to 30% (Tanke et al 1994; Roy et al 
2002), autopsy ﬁ  ndings report UVC-related TE in 20% to 
65% of neonates who have an UVC in place at the time of 
demise (Tanke et al 1994; Khilnani et al 1991; Schmidt 
and Zipursky 1984). In a study investigating children who 
underwent umbilical vein catheterization, clinically silent 
portal vein thrombosis (PVT) was found in astonishingly 
many, namely 43%, of neonates studied. Complete or partial 
revascularization occurred in only 56% of these patients 
(Kim et al 2001). Another study investigating children 
with PVT found that 73% had a history of UVC placement 
(Morag et al 2006).
As in venous TE, the incidence of arterial thrombosis 
is extremely dependent on the method used to diagnose 
the event. Whereas clinical signs and symptoms occur in 
1%–3% of babies with UAC, ultrasound-based studies report 
an incidence of 14% to 35%. Ion angiographic investiga-
tions, on the other hand, report an incidence of up to 64% 
(Cohen et al 1995).
There are only few studies published on the distribution of 
neonatal thrombosis or TEs. The synopsis of these few reports 
is that whereas arterial TEs other than neonatal stroke or renal 
artery thrombosis are usually found at the site of insertion 
of an arterial catheter or arterial vascular access, venous 
thromboses are predominantly located in the renal vein, portal 
vein, and the inferior and superior vena cava (Nowak-Gottl 
et al 1997). Other frequently affected locations include the 
femoral and axillary veins and the right atrium.
Neonatal arterial ischemic stroke is most frequently 
caused by large vessel infarcts involving the carotid circula-
tion in more than 2/3 of cases (Andrew et al 2001). In many 
of these infants, either perinatal complications or cardiac 
disease can be identiﬁ  ed (Golomb et al 2001).
Pathophysiology
If we consider the multiple additive factors that contribute 
to the development of thromboembolism in the critically ill 
neonate, it becomes obvious why the neonatal period is more 
prone to symptomatic or asymptomatic TE than all other 
periods in infancy, childhood and early adulthood.
Developmental hemostasis
The concept of the hemostatic system in a dynamic 
development during infancy and childhood was first 
introduced by Andrew and colleagues in 1988 and 1990 
(Andrew et al 1988; Andrew et al 1990). These changes 
in plasmatic, cellular and vessel wall components of 
hemostasis are obviously important in diagnosis, treatment 
and prevention of thrombosis in a critically ill neonate.
Although the hemostatic system of the term and preterm 
neonate is signiﬁ  cantly different from that of children and 
adults, most authors refer to the hemostatic potential of the 
“healthy” neonate as being balanced, neither promoting 
hemorrhage nor thrombosis.
On the pro-coagulant side, especially the vitamin 
K-dependent coagulation factors (II, VII, IX, and X) and the 
components of the contact system (FXI, FXII, prekallikreine 
and high molecular weight kininogen) show signiﬁ  cantly 
reduced plasma activities in neonates compared to children 
and adults. Although interpretation of values requires cau-
tion as corrected gestational age plays a major role, plasma 
activities of these components can be as low as 30% in the 
neonate versus 80% to 120% in adults. Adult plasma con-
centrations are not achieved before the sixth month of life. 
However, the vitamin K-dependent inhibitors of coagulation, 
protein C and protein S, are also reduced in the neonatal 
period, counterbalancing the reduced clotting potential of 
neonatal plasma. In fact, both antithrombin and protein 
C concentrations are decreased to approximately 30% of 
adult values in term and even lower in preterm newborns. 
Neonatal platelets have been reported to be hypo-reactive; 
however, this deﬁ  ciency seems to be balanced by increased 
von Willebrand factor activity, resulting in overall normal 
platelet function.
The activity of the ﬁ  brinolytic system in the newborn is 
reduced compared to adults and older children due to both 
decreased plasma activity of plasminogen and increased 
plasma levels of plasminogen activator inhibitor (PAI). The 
latter fact may explain the high rate of TE associated with 
intravascular devices in newborns; however, to date there 
is no evidence that the neonatal hemostatic system either 
protects from or promotes thrombus formation. Of course, 
additional risk factors, eg, critical illness or congenital 
thrombophilia, have to be considered separately from the 
immaturity of neonatal hemostasis. Given the signiﬁ  cant 
differences between the plasma factor concentrations in 
different age groups, a detailed knowledge on the develop-
ment of hemostasis is critical for the intensivist in order to 
adapt pharmacological approaches and interpret results from Vascular Health and Risk Management 2008:4(6) 1339
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laboratory tests in the neonate with TE (Ignjatovic et al 2006; 
Ignjatovic et al 2007).
Acquired thrombophilia in critical illness 
and sepsis
Critical illness is a well-recognized risk factor for TE in all 
age groups. Immobilization, rapid changes in intravascular 
volume and extensive intravascular instrumentation 
contribute to the enhanced risk of venous and arterial throm-
bosis in patients in intensive care units. In neonates, this risk 
is further increased by the fact that indwelling catheters are 
large compared to the diameter of the vessel, in most cases 
obstructing approximately 50% of the lumen. Hence, it is 
not surprising that almost 90% of thromboembolic events 
in neonates are caused by intravascular devices.
Additional risk factors include, but are not limited to, 
asphyxia, maternal diabetes, poor cardiac output and dehy-
dration. Neonates are born with a high hematocrit and tend 
to contract their intravascular volume within the ﬁ  rst days 
of life, making them even more prone to thromboembolic 
events.
Sepsis is a signiﬁ  cant cause of morbidity and mortality 
in neonates and in adults. The annual combined mortality 
caused by sepsis in all age groups equals the death rate of 
myocardial infarction (Angus et al 2001). Sepsis alone is 
responsible for 7% of all childhood deaths (Watson et al 
2003). In the neonatal population, sepsis is particularly 
devastating, as this disease causes 45% of late deaths in the 
NICU (Meadow et al 2002). Neonates with sepsis develop 
an acquired pro-thrombotic state due to increased consump-
tion of already limited supplies of coagulation inhibitors. 
Furthermore, plasma activity of PAI-1 is increased in 
sepsis and levels of protein C are reduced. The latter fact 
has been reported to correlate with poor outcomes in adults 
and neonates. Ongoing consumption of coagulation fac-
tors and platelets resulting in microcirculatory thrombosis 
likely contributes to sepsis-induced multi-organ failure and 
death. Macro-circulatory thrombotic events are rare in this 
setting but can occur, especially in babies who have UACs 
or UVCs in situ.
Congenital thrombophilia
Whereas congenital thrombophilia was described not to be 
associated with UVC thrombosis in one report (Turebylu 
et al 2007), Heller and colleagues published data from the 
childhood thrombophilia study group indicating an elevated 
odds ratio for the presence of congenital thrombophilia in 
neonates with renal, portal, or hepatic venous thrombosis 
(Heller et al 2000). A recent study conﬁ  rms a high prevalence 
of inherited thrombophilia in neonatal stroke (Suppiej et al 
2007). Heller and colleagues recommended that neonates 
with TE should undergo an extensive screening, includ-
ing resistance to activated protein C (APC-R), protein C, 
protein S, and antithrombin activity, concentration of clot-
table ﬁ  brinogen, plasminogen activity, activities of coagula-
tion factors VIIIC and XII, Lp(a), histidine-rich glycoprotein, 
heparin cofactor II, antiphospholipid antibodies, lupus 
anticoagulants, as well as fasting homocysteine concentra-
tions. In addition, DNA-based assays (ie, factor V G1691A 
mutation, factor II G20210A variant and MTHFR C677T 
genotype) should be performed (Heller and Nowak-Gottl 
2003). Whereas DNA-based mutation analysis can be per-
formed at any time point, protein-based assays should not 
be carried out in the ﬁ  rst 6–8 months after the event and 
oral anticoagulation is recommended to be discontinued at 
least 14–30 days before plasma samples for thrombophilia 
diagnosis are drawn (Heller and Nowak-Gottl 2003).
An obvious clinical picture is associated with either homo-
zygous or double heterozygous congenital protein C deﬁ  -
ciency. These infants develop the life-threatening complication 
of purpura fulminans within the ﬁ  rst days of life (Kreuz et al 
1998). Notably, patients with prothrombotic mutations 
and polymorphisms are most likely to develop thrombosis 
when triggering elements, such as placement of catheters, 
prolonged immobilization, or surgery, are also present.
Congenital heart disease
Infants and young children with cyanotic heart disease are 
at risk for thrombotic events, including shunt thrombosis, 
coronary artery thrombosis, and thromboembolic arterial 
stroke (Israels and Michelson 2006). Cyanotic congenital 
heart diseases (CHD) with secondary polycythemia and a 
hyperviscous state are associated with a reduction in blood 
ﬂ  ow and subsequent thrombosis. In CHD, the incidence 
of venous TE in infants 6 months of age is about 50% 
and even higher in arterial TE (70%) (Monagle 2004). 
The increasing number of surgical procedures carried out 
in the neonatal period potentiates the risk for TE events. 
Trans-catheter interventions in newborns, which are mostly 
performed using venous access from the femoral or umbilical 
vein, incur the risk for transient or permanent occlusion of 
the lower body veins. In complex heart disease with the 
possibility of right-to-left shunt, paradoxical embolism may 
occur. Prenatally, the Eustachian valve directs the blood 
from the umbilical vein and the lower body to the foramen 
ovale and to the left atrium. Postnatally, emboli may take the Vascular Health and Risk Management 2008:4(6) 1340
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same route to the systemic circulation, thus increasing the 
risk for a thromboembolic incident when femoral catheters 
or UVC are used compared to central venous lines from the 
upper body.
We and others reported a 12% incidence of aortopulmo-
nary shunt thrombosis in a prospective multicenter observa-
tional study (Li et al 2007), indicating a hypercoagulable state 
of cyanotic children after insertion of intravascular artiﬁ  cial 
prostheses. Furthermore, acquired thrombophilia in cyanotic 
children has been described in terms of elevated markers as 
platelet p-selectin, and decreased levels of thrombomodulin 
and protein C activity (Kajimoto et al 2007). Patients with 
cyanotic congenital heart disease usually undergo a preopera-
tive analysis of the well known genetic aberrations associated 
with increased thrombotic potential, eg, the Factor V Leiden 
and the MTHFR mutations. In patients with thrombosis after 
cardiac surgery, in which the classical screening parameters 
were normal, Ozbek and colleagues recently described other 
polymorphisms that included a higher frequency of the pro-
thrombotic angiotensin 1 converting enzyme deletion/dele-
tion genotype, and a lower frequency of the antithrombotic 
alpha ﬁ  brinogen Thr/Thr genotype (Ozbek et al 2005).
Diagnosis
Clinical
The clinical picture of vascular incidents in neonates is 
extremely variable and largely dependent on the location and 
the size of the thrombus or embolus. Presentation may vary 
from discrete symptoms or asymptomatic events to life or limb 
threatening acute events. Although in the following sections 
TE will be categorized as arterial, venous, and CNS events, 
one needs to keep in mind that several right-to-left (ie, veno-
arterial) shunts remain patent for a considerable time even in 
the term neonate. Thus, a paradoxical embolus cannot be ruled 
out even in the absence of congenital heart disease.
Arterial
Arterial vascular events, accounting for about half of all 
TE in the neonatal population, are almost always directly 
related to arterial vascular catheterization of central or 
peripheral arteries. This underscores the need for meticulous 
clinical observation in children with arterial access in place. 
Obvious signs include ischemia of limbs or trunk, pale or 
cold extremities distal to the catheterization site, weak or 
absent palpability of the pulse (pulse oximeters will also 
show this) and decreased or immeasurable blood pressure. 
Signs of necrotizing enterocolitis such as feed intolerance, 
bilious gastric aspirates, blood-stained stools, and bowel wall 
pneumatosis in an infant with UAC should raise the suspicion 
of mesenteric infarction. Diagnostic work-up for renal failure 
in children with UAC should include a Doppler ﬂ  ow study 
of the renal arteries to avoid missing out on the diagnosis of 
renal artery thrombosis. Elevated blood pressure might also 
hint at decreased renal perfusion.
There are some reports of aortic thrombosis in the neonate 
mimicking coarctation of the aorta with signiﬁ  cant blood 
pressure differences in upper and lower body blood pressure 
readings; thus, the simple investigation of upper and lower 
body blood pressure measurements should be performed in 
any infant with hypertension diagnosed by measurements 
obtained from the upper body.
Venous
Limb swelling, pain, and cyanotic or hyperemic color should 
raise the suspicion of venous thrombosis. Renal vein throm-
bosis may present with an abdominal mass and hematuria 
or proteinuria; hence, these symptoms should ring a bell 
especially in neonates with risk factors such as prematurity, 
asphyxia, critical illness, femoral CVL, and male sex (Kuhle 
et al 2004; Bokenkamp et al 2000).
Signs of impaired liver function, hepatomegaly and 
splenomegaly should raise the suspicion of PVT; however, 
only about 10% of children with PVT develop acute clinical 
symptoms (Morag et al 2006). Thrombosis of the inferior 
vena cava can present with signs resembling obstruction of 
the renal vein (hematuria, retroperitoneal mass); however, 
these will occur bilaterally when the inferior vena cava is 
affected. In addition, the lower limbs may be edematous and, 
if blood ﬂ  ow is substantially impaired, the child may be in 
respiratory distress and may have high blood pressure.
Pulmonary embolism
Pulmonary embolism (PE) is a rare event in the neonatal 
period. Clinical signs of massive ventilation/perfusion mis-
match, difﬁ  cult oxygenation, and signs of right heart failure 
should raise the suspicion of PE, especially in babies with 
congenital heart disease. In the few cases reported in the 
literature, diagnosis of PE was conﬁ  rmed by lung perfusion 
scans or angiography (Feldman et al 2005; Gamillscheg et al 
1997; Moreno-Cabral and Breitweser 1983).
Central nervous system
In contrast to the clinical picture in adults, neonatal stroke 
does not usually present with hemiplegia. The leading clini-
cal symptoms in central nervous system TE in neonates are 
seizures and lethargy. The diagnosis of ischemic stroke as 
well as of sinus vein thrombosis can initially be conﬁ  rmed Vascular Health and Risk Management 2008:4(6) 1341
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by cerebral ultrasound through the open fontanel followed 
by cranial magnetic resonance imaging (MRI).
Post-thrombotic syndrome
TEs that remain clinically asymptomatic in the neonatal 
period can become evident later in life when children or 
adolescents present with venous collaterals, post-thrombotic 
syndrome (featuring edema, purpura, eczematous dermatitis, 
pruritus, ulceration, and/or cellulitis), reduced limb growth 
or other late complications such as portal hypertension. Any 
of these symptoms can be the result of a vascular accident 
in the neonatal period. See also Reassessment, below, for 
more detail (Table 1).
Imaging
Ultrasound
Imaging by using either echocardiography or abdominal 
ultrasound is the most commonly applied diagnostic method 
to conﬁ  rm clinical suspicion of TE or to screen babies for 
clinically silent disease. However, despite its advantages 
as point of care testing (minimal invasiveness and no use 
of radiation), the overall performance of ultrasound to 
detect thrombi is poor. One study comparing echocardio-
graphic investigations to venograms reported a sensitivity 
of 21%–43% and speciﬁ  cities ranging from 76% to 94% 
(Roy et al 2002). This study concluded that venography 
is required to accurately diagnose UVC related TE in neo-
nates. Since in this study 4% of all infants investigated were 
incorrectly diagnosed as having central venous thrombosis, 
the conﬁ  rmation with contrast venography might avoid 
exposing an infant unnecessarily to potentially hazardous 
treatment.
Contrast venogram
Still regarded as the gold standard in the diagnosis of neo-
natal catheter-induced TE, a contrast venogram exposes the 
infant to radiation and contrast agent. A recent study, using 
1.5 to 2 ml of iohexol™ administered by hand injection over 
1 to 2 sec and ﬂ  uoroscopy times of 5–15 sec, reported a 100% 
agreement between two blinded radiologists about presence 
or absence of thrombi. In one of 14 babies with thrombosis 
a disagreement between the two examiners was reported in 
regards to the extension of the thrombus. A portable image 
intensiﬁ  er allows contrast venography to be performed on 
the NICU as long as radiation exposure guidelines are taken 
into consideration (Roy et al 2002).
MRI angiography
MRI angiography is recommended for the diagnosis of isch-
emic neonatal stroke and is an option in neonatal pulmonary 
embolism. The need for transport limits the practicability 
in the most critically ill and very preterm neonatal patients.
Laboratory
Initial laboratory work-up in a neonate in whom throm-
bosis is suspected should include a full blood count as 
Table 1 Clinical signs and symptoms of thromboembolism in critically ill neonates
Early Extremities Intestine Kidney Aorta CNS Lung
Arterial Extremities pale 
and/or cold 
Pulse weak or absent
Blood pressure 
reduced
Feed intolerance 
Gastric aspirates bilious
Stools bloody 
Bowel wall pneumatosis
Blood pressure 
elevated
Blood pressure 
higher in arms 
than in legs
Lethargy 
Seizures 
(NO hemiplegia)
Right heart failure 
Oxygen 
saturation low 
Ventilation/perfusion 
mismatch
Venous Portal vein Inferior vena cava
Swelling
Pain
Cyanosis
Hyperemia
Liver function impaired 
Splenomegaly
Hematuria
Proteinuria
Abdominal mass
Hematuria
Lower limb edema
Both kidneys palpable
Respiratory distress
Lethargy Seizures
Late Portal vein Inferior vena cava
Venous collaterals
Limb growth 
reduced
Post-thrombotic 
syndrome
Portal hypertension
GI hemorrhage
Hepatic atrophy 
Splenomegaly
Blood pressure 
abnormalities
Leg and abdominal 
pain Varicose veins
Post-thrombotic 
syndrome
Neurodevelop-
mental delay
Cognitive 
impairment
Cerebral palsy
Right heart 
hypertrophy
Abbreviation: GI, gastrointestinal.Vascular Health and Risk Management 2008:4(6) 1342
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well as a coagulation screening with determination of 
prothrombin time, thrombin time and activated partial 
thromboplastin time.
D-dimers
D-dimers, which are elevated as an acute phase reaction 
in all patients with infection or systemic inflammatory 
response syndrome (SIRS), are a positive ﬁ  nding in almost 
all critically ill neonates. Conversely, negative D-dimers are 
relatively accurate in ruling out thrombosis in most patients, 
including neonates.
Platelets
In almost all neonates, platelet numbers decrease after birth. 
However, a sudden and severe drop in platelet counts should 
alert the intensivist. Although the differential diagnosis 
for thrombocytopenia in the neonate is broad, including 
auto- and allo-antibodies as well as effects of medications 
and consumption, thrombocytopenia remains one of the most 
sensitive indicators for micro- (in the setting of sepsis) or 
macro-circulatory thrombosis.
Prevention
Obviously, strategies to prevent thrombus formation are 
of utmost importance in critically ill neonates. Since the 
majority of TE in neonates is catheter-related, optimal 
management and careful consideration of the necessity of 
these devices might give the intensivist a unique chance to 
improve outcome. Since even small thrombi might act as a 
nidus for infection, prevention of clot formation is of double 
beneﬁ  t for the patient.
Umbilical catheters
Data suggest that UAC-related thrombosis can be 
minimized by high umbilical positioning, end-hole 
and single-lumen construction (Barrington 2000; Barrington 
2000). Low-dose heparin infusion is recommended for 
UACs with some studies suggesting that even low doses 
0.25 IU/ml are effective (Barrington 2000). The incidence 
of heparin-induced thrombocytopenia (HIT II) in preterm 
newborns seems to be extremely low, thus promoting the 
use of unfractionated heparin (UFH) to ensure line patency 
(Kumar et al 2004).
Time in situ should be minimalized and many neona-
tologists would see no indications for a UAC in a baby 
with stable hemodynamics and low to moderate ventilation 
parameters (Fletcher et al 1994). Although some reports 
indicate that indwelling UACs in sick infants may not carry 
an increased risk of thrombosis during the ﬁ  rst 5 days of 
use (Coleman et al 2004), a study published by Boo and 
colleagues showed that the only signiﬁ  cant risk factor associ-
ated with the development of abdominal aortic thrombosis 
following insertion of UAC was longer duration of UAC in 
situ (for every additional day of UAC in situ, adjusted OR of 
developing thrombosis was 1.2, 95% CI: 1.1, 1.3; p = 0.002) 
(Boo et al 1999). When the use of UVC was audited by the 
study group for complications in perinatal care, it become 
apparent that UVC were inserted in approximately 50% of 
infants with a birth weight of 1000 g or less (Seguin et al 
1994). Heparin was used in the infusate in the majority of 
the participating centers. As in UACs, the duration of use 
seems to be of importance in avoiding thrombus formation. 
In the report of the study group, the UVC was removed 
after a median of 4.4 days, the Center for Disease Control 
recommends removal after 14 days at the latest (O’Grady 
et al 2002). However, one study recently compared long- and 
short-term use of UACs in premature neonates and did not 
ﬁ  nd an increased risk of thrombosis in the long-term group 
in which UACs were in situ for up to 28 days (Butler-O’Hara 
et al 2006). Nevertheless, 9 of the 45 small for gestational 
age babies in the study developed a thrombus which was 
detected by echocardiography.
Other central venous catheters
Whereas percutanously placed peripheral silastic catheters in 
general have a lower incidence of thrombosis compared to 
centrally placed catheters, the highest incidence in CVCs is 
seen in femoral lines. Internal jugular access shows a lower 
rate of thrombosis compared to subclavian (Male et al 2005). 
Heparin infusion is utilized in most centers for CVCs in 
neonates, especially for those placed in the femoral vein.
The effectiveness of heparin infusion in percutanously 
placed peripheral silastic catheters has been controversial: 
A 2005 Cochrane review did not recommend the routine 
use of heparin for silastic catheters (Shah and Shah 2005), 
whereas a recently published prospective study documented 
lower catheter occlusion rates but similar incidences of 
thrombosis in the heparin vs the placebo group (Shah et al 
2007). These ﬁ  ndings lead to the publication of an update 
of the 2005 Cochrane review in 2008, in which the use of 
heparin at a dose of 0.5 IU/kg/h is recommended to maintain 
line patency, although this regimen does not reduce the risk 
of catheter-related thrombosis (Shah and Shah 2008).
Heparin-coated catheters might become an interesting 
option in the future to prevent both catheter occlusion as 
well as catheter-related thrombosis. However, a recent Vascular Health and Risk Management 2008:4(6) 1343
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Cochrane review could not yet confirm a clear advantage 
of heparin-coated catheters in children (Shah and Shah 
2007) and studies in neonates have not yet been under-
taken.
Management
Acute
When to treat TE in critically ill neonates is a challenging 
question for everybody involved in the care of these infants. 
Since withholding anticoagulation is an equally active deci-
sion as commencing treatment, the individual risk/beneﬁ  t 
ratio has to be carefully considered.
Potential beneﬁ  ts of antithrombotic therapy include com-
plete or partial re-canalization of the obstructed vessel with 
consequently decreased tissue hypoperfusion in the affected 
area; limb saving in the scenario of acute arterial occlusion; 
avoidance of detrimental long term morbidity from condi-
tions such as portal hypertension, hepatic post thrombotic 
syndrome, renal hypertension, impaired renal function, renal 
shrinkage, discrepancies in limb growth, claudication, and 
paraplegia.
The major potential risk of antithrombotic therapy, 
especially in neonates, is a hemorrhagic event that is poten-
tially massive and life threatening, in particular intracranial 
hemorrhage. Since low molecular weight heparins show a 
particularly favorable risk/beneﬁ  t ratio, the decision not to 
treat TE will most likely be restricted to those infants with 
an exceptionally high risk of hemorrhage, eg, very immature 
preterm neonates within the ﬁ  rst days of life or established 
intraventricular hemorrhage (IVH). Other relative contrain-
dications for anticoagulant therapy include thrombocytopenia 
with platelet counts of less than 50 G/L and history of high 
grade IVH. In most other patients, heparin therapy might be 
considered appropriate for clinically symptomatic TE.
The appropriateness of thrombolytic therapy will always 
depend on the individual patient. However, since the risk 
of hemorrhage, especially in systemic allied thrombolytic 
therapy remains unclear, most would restrict this therapeutic 
approach to life or limb threatening vessel obstructions.
Guidelines on treatment of clinically asymptomatic clots 
(detected for example during routine imaging in critically ill 
neonates) are not published and individual decision-making 
remains necessary. A majority of clinicians might decide to 
treat clots which obstruct more than 50% of the lumen of a 
major vessel (including the portal venous system) with low 
molecular weight heparin (LMWH) in the absence of contra-
indications. This approach takes both the potential long-term 
consequences of even asymptomatic TE in major vessels 
(see Follow-up, below) as well as the potential danger that 
the thrombus size may increase into account.
Medical
Unfractionated heparin
Unfractionated heparin has been the standard medication 
for prophylaxis and treatment of TE for many years. Due to 
unfavorable pharmacokinetics and pharmacodynamics and 
the imminent danger of HIT, UFH was almost completely 
replaced by low molecular weight heparins in adult medicine 
with the exception of anticoagulation during extracorporal 
circulation. In neonatal medicine, however, UFH are still 
widely used to prevent and treat TE. Despite the lack of 
studies on LMWH in the neonatal population, the low inci-
dence of HIT II (Kumar et al 2004), and the availability of 
protamine for potential reversal of UFH action, support its 
use in preterm and term neonates. Dosages of 25 IU/kg/h 
are usually required to achieve a targeted prolongation of the 
aPTT to 70 sec and above.
Low molecular weight heparin
Low molecular weight heparin has widely replaced UFH in 
prophylaxis and treatment of acute TE in adult patients due 
to superior efﬁ  cacy, safety and pharmacokinetics. In neonatal 
patients, the data available are still limited. However, LMWH 
is increasingly used in NICU in the post-acute treatment of 
venous and arterial TE as well as in prevention of thrombosis 
in high-risk patients. Subcutaneous enoxaparin seems to be the 
most frequently used substance in term and preterm neonates. 
Data published on the use of enoxaparin in 12 preterm and 4 
term infants found no serious adverse events and a resolution 
of TE in 71% of the patients (Malowany et al 2007).
Anti-Xa level is usually targeted at 0.4–0.6 IU/ml in 
prophylaxis and at 0.6–0.8 IU/ml in treatment scenarios. 
Preterm infants require longer to achieve an anti-Xa level 
within target range compared to term infants (6 vs 2 days) 
and were found to require higher doses of enoxaparin 
(2.1 mg/kg/12 h vs 1.7 mg/kg/12 h) (Streif et al 2003). Recent 
evidence also suggests a starting dose of 1.7 mg/kg/12 h in 
term and 2 mg/kg/12 h in preterm neonates (Malowany et al 
2008). Efﬁ  cacy was reported to be 59%–100%. Cessation of 
anticoagulation can be achieved by terminating the medica-
tion 12–24 h prior to planned surgical procedures. In contrast 
to common belief, protamine is able to antagonize anti-Xa 
activity of LMWH in part and anti-IIa activity of LMWH 
completely (Crowther et al 2002). In a recent case report, 
an overdose of 40 mg of enoxaparin in a neonate was suc-
cessfully antagonized with 35 mg of protamine given in the 
preceding 4.5–7.5 h (Wiernikowski et al 2007).Vascular Health and Risk Management 2008:4(6) 1344
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Streptokinase
Streptokinase is infrequently administered in the neonatal 
period due to decreased ﬁ  brin speciﬁ  city and high antige-
nicity compared to rtPA. In the few patients described in 
the literature, doses of 1000–2000 IU/kg/h have been used 
(Nowak-Gottl et al 1997; Hausler et al 2001).
rtPA (recombinant tissue plasminogen activator)
If thrombolytic therapy is utilized, rtPA is mostly favored 
due to high ﬁ  brin speciﬁ  city with poor activation of free 
plasmin, lack of antigenicity and short half life (4 min in 
plasma, 45 min for thrombolytic effects). Dosing varies 
between different reports, ranging from 0.3 to 9 mg/kg/24 h. 
Plasminogen levels are low in neonates compared to adults, 
pointing towards a possible requirement for higher doses of 
rtPA. Administration of fresh frozen plasma (FFP) prior to 
utilization of thrombolytics may increase success rates by 
providing sufﬁ  cient plasminogen levels. Frequent monitoring 
of ﬁ  brinogen levels and FFP administration if ﬁ  brinogen lev-
els fall below 100 mg/dl are required. For safety and efﬁ  cacy 
of systemic thrombolysis in neonates see below.
Urokinase
As with streptokinase, the decreased ﬁ  brin speciﬁ  city and 
the antigenicity of urokinase compared to rtPA limit its use in 
neonates. In the small number of neonatal patients which are 
described in the literature, doses of 1000 up to 10.000 IU/kg/h 
have been reported, although the majority of patients received 
2000 IU/kg/h or less (Nowak-Gottl et al 1997; Hausler et al 
2001; Duncan et al 1991; Grifﬁ  n and Casta 1988; Distefano 
et al 2000; Kobayashi et al 2006).
Some studies, which include small numbers of term 
neonates, investigated urokinase as treatment or prevention 
of catheter occlusion and/or catheter infection with some 
success in older children and adults (Dillon et al 2004; Svo-
boda et al 2004). However, this treatment is not sufﬁ  ciently 
evaluated in the neonatal population to be recommended.
Duration of treatment
The administration of ﬁ  brinolytics such as rtPA, strepto-
kinase, and urokinase is usually rather short in duration. 
These agents are stopped either after a few days or when 
revascularization has been achieved (as determined clinically 
or via imaging). In contrast, LMWH is increasingly used in 
therapeutic concentrations for prolonged therapies of 6 weeks 
or even up to 3 months, since late revascularization occurs in 
adults (Agnelli and Becattini 2008; Hull et al 2006) and in 
children and neonates, as the few studies performed in these 
patient groups have shown (Nowak-Gottl et al 2008).
Interventional
Catheter-directed thrombolysis
Catheter-directed thrombolysis (CDT) has been reported 
in 13 patients in the neonatal period (Anderson et al 1991; 
Aspesberro et al 1999; Dillon et al 1993; Gerling et al 2002; 
Khan et al 2008; Klinge et al 1998; Pritchard et al 1985; 
Rehan et al 1994; Ries et al 2002; Rogers et al 1989; Ryan 
and Andrew 1992; Wang et al 2003). In these reports, rtPA 
(dosage 0.01–0.1–0.5 mg/kg/h [min–median–max]) was 
used in 8 patients, while 4 patients received streptokinase 
and one was treated with urokinase. In contrast to systemic 
thrombolytic therapy, efﬁ  cacy of CDT seems to be superior 
(82% vs 62% of complete clot lysis, 16% vs 8% partial clot 
lysis, 8% vs 21% failure). The safety proﬁ  le also favors 
CDT with a rate of one intraventricular hemorrhage (IVH) in 
13 patients with CDT compared to 2 IVH, one intra abdomi-
nal bleed, one kidney rupture, one mucosal bleed and one 
puncture site bleed in 38 neonates with systemic thrombolysis 
(Khan et al 2008).
Other catheter interventions
Mechanical thrombectomy has been reported in a neonate 
with pulmonary embolism after surgery for congenital heart 
disease (Moreno-Cabral and Breitweser 1983). Availability 
of small catheters (4F) allow nonwall-contact procedures, 
breaking the thrombus by circulating ﬂ  uids and thrombus 
removal by suctioning and aspiration of the thrombotic 
material (Angiojet, Possis, Hydrolizer, Cordis). Successful 
hydrodynamic (Angiojet) catheter-based thrombectomy has 
been described in neonates with postoperative pulmonary 
embolism (Feldman et al 2005; Kobayashi et al 2006). 
Possible side effects such as hemolysis, blood loss and bra-
dycardia may be more pronounced in neonates. The use of 
the classical Fogarty catheter may be useful in arterial limb 
ischemia in neonates 1500 g. Wall contact procedures such 
as clot maceration brushes have not been used in the neonatal 
period and carry in general the risk of late post-thrombotic 
syndrome, when applied in venous thrombosis due to rupture 
of venous valves (Figure 1).
Surgical
Surgical clot removal and vessel reconstruction may become 
necessary in the rare event of life or limb threatening arterial 
thromboembolism and in the even rarer event of massive 
venous thrombosis. A treatment protocol including surgical 
intervention for infants with brachial artery thrombosis has 
been published by Coombs and colleagues (Coombs et al 
2006). However, due to the high rate of re-occlusion of the Vascular Health and Risk Management 2008:4(6) 1345
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affected vessel, embolectomy is avoided if at all possible 
(Monagle et al 2004).
Successful surgical embolectomy has been described in neo-
nates with life threatening pulmonary embolism (Gamillscheg 
et al 1997; Moreno-Cabral and Breitweser 1983).
Follow-up
Long-term anticoagulation
In the absence of solid data the need for long-term antico-
agulation in neonates with symptomatic TE is debatable. 
Most clinicians would agree not to treat catheter-induced 
thrombosis in a patient without congenital thrombophilia 
with long-term anticoagulation. However, in patients with 
single prothrombotic traits, anticoagulation for 3 to 12 months 
after the onset of the event is recommended (Heller and 
Nowak-Gottl 2003). Although data published by Kurnik 
and colleagues give evidence that symptomatic recurrent 
thromboembolism is not common in children with neonatal 
arterial ischemic stroke(Kurnik et al 2003), anticoagulation 
with LMWH or low dose aspirin in children with arterial 
vascular occlusion or ischemic stroke is recommended by 
some (Heller and Nowak-Gottl 2003; Strater et al 2001).
Warfarin
The use of warfarin in the neonatal period is problematic. 
Many formula fed infants receive large amounts of  vitamin K 
in the formula and thus are almost resistant to warfarin. Dos-
ing in small children is difﬁ  cult since liquid formulations 
are not commercially available and customized suspension 
of tablets does not provide sufﬁ  cient accuracy in dosing. 
If warfarin is used beyond the neonatal period, training of 
parents in point of care coagulation test devices in patient 
self control programs can be of great help in ensuring INR 
levels within the desired target range.
Aspirin
Platelet function is reduced in neonates in comparison to 
adult and older children. Anti-platelet agents such as aspirin 
or the newer agent clopidogrel are traditionally used in occlu-
sion prophylaxis in patients with congenital heart disease 
and shunt-dependent pulmonary or systemic circulation. In 
contrast to the use of aspirin as prophylaxis in patients with a 
history of TE, there is no evidence that anti-platelet therapy is 
effective as treatment in acute venous or arterial neonatal TE. 
Neonates with cyanotic congenital heart disease palliated 
with a shunt who present with abnormal laboratory ﬁ  ndings 
suggestive of an increased risk for developing thrombosis 
should be treated with platelet aggregation inhibitors.
Clopidogrel
Clopidogrel (Plavix), a thienopyridine derivative, selectively 
inhibits the binding of ADP to its platelet receptor and the 
subsequent ADP-mediated activation of the glycoprotein 
IIb/IIIa complex, thereby inhibiting platelet aggregation 
and reducing the formation of arterial and venous thrombi 
(Coukell and Markham 1997). Recently a prospective, 
multicenter, randomized, double-blind, placebo-controlled, 
dose-ranging study showed a dosage of 0.2 mg/kg once daily 
to be effective in neonates and infants with CHD in terms of 
achieving a mean of 30% to 50% inhibition of ADP–induced 
platelet aggregation (Li et al 2008). Administration of higher 
doses of clopidogrel, extrapolated from adult dosing carries 
vitamin K  antagonists
eg warfarin
mechanical clot lysis
cateter interventions
platelet antagonists
eg ASA or colpidorel
X
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the risk of bleeding in high risk patients especially when used 
in conjunction of Aspirin (Soman et al 2006). Side effects of 
clopidogrel seem to be lower than in the other thrombocyte 
aggregation blocking agents. An upcoming study evaluating 
the efﬁ  cacy in preventing TE will elucidate the risk and 
beneﬁ  t of this drug in neonates and infants.
Re-assessment
Portal hypertension (PHTN), which is the major cause of 
gastrointestinal (GI) hemorrhage in children, is the one of 
the most severe long-term consequences of UVC associated 
portal vein obstruction. PHTN is diagnosed at a mean of 
5.7 years after the acute event (Alvarez et al 1983). Children 
with portal obstruction have a history of UVC placement in 
the neonatal period in 70% of the cases (Morag et al 2006). 
It might be worthwhile to investigate children with UVC 
history for signs of PHTN if left lobe hepatic atrophy, sple-
nomegaly, thrombocytopenia or gastrointestinal hemorrhage 
is noticed.
The occurrence of post-thrombotic syndrome is increas-
ingly reported in follow-up studies in preterm neonates. In a 
study published by Hausler and colleagues following up on 
40 infants and children with IVC thrombosis complete restitu-
tion was found in only four cases. Persisting iliac and/or caval 
venous obstruction occurred in 17 patients, including six with 
initial thrombolysis. Varicose veins were found in 12, and post-
thrombotic syndrome in seven of these cases. According to 
Kaplan-Meier analysis, 30% of patients with persisting venous 
disease will develop post-thrombotic syndrome within 10 years 
of the thrombotic event (Hausler et al 2001). This underlines 
the importance of achieving the best possible vascular status in 
the initial treatment attempt, since post-thrombotic syndrome 
can be prevented by successful thrombolysis in children 
(Goldenberg et al 2007). Consequently, the risk of treatment 
in the initial event must be carefully judged against the risk of 
missing out on treatment.
Long-term complications of arterial thrombosis include 
hypertension, impaired renal function, discrepancies in limb 
growth, claudication and paraplegia. Patients with a history 
of arterial thrombosis therefore need a regular follow-up.
Conclusion
Critically ill neonates are at major risk of venous and arterial 
thromboembolic events. Since indwelling catheters are the 
main contributing factor, a signiﬁ  cant proportion of these 
events might be preventable by critically re-evaluating 
especially the indication for umbilical artery and venous 
catheter on a daily basis and using heparin prophylaxis in 
those babies where catheterization of the umbilical vessels 
cannot be discontinued.
While therapy of established thrombus formation with 
unfractionated or low molecular weight heparin needs to be 
weighed carefully against the “lost chance” of not applying 
therapy, thrombolysis or mechanical clot removal should 
be restricted to the rare scenarios of acute life threatening 
vessel occlusion.
All neonates with a history of thromboembolic events 
warrant a follow-up with an emphasis on the development 
of post-thrombotic syndrome, portal hypertension and an 
investigation for congenital thrombophilic risk factors. 
A detailed knowledge of developmental hemostasis is nec-
essary to guide therapy and monitoring in neonates with 
thrombotic events.
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